Swedish research has helped to screen anti-cancer drug testing methods

Stockholm, June 6th, Caroline Medical School, Sweden, said on the 5th that their researchers have developed a new method that can easily determine the DNA synthesis of pathogen cells or cancer cells. This method can also be used to test the effectiveness of new drugs against drug-resistant pathogens and cancers, and to facilitate the screening of new drugs.

This research by Toland, a researcher at Caroling Medical School, and Dean Fowler, a professor at Stockholm University, is based on the detection of ribonucleotide reductase (RNR). This enzyme is essential for DNA synthesis and cell proliferation and can be used as a "target" for antibacterial drugs and anticancer drugs. However, because the current technology is still difficult to deal with this enzyme, there are still few successful drugs on the market.

Swedish researchers have designed a variant polymerase chain reaction that, combined with high-throughput screening technology, allows ribonucleotide reductase changes to be measured. This means that it is easy to determine the proliferation of pathogen cells or cancer cells, and it can also be used to screen and detect drugs targeting ribonucleotide reductase.

The researchers reported in a new issue of the National Academy of Sciences that, with this method, they have screened more than 1,300 substances for the inhibition of resistance by inhibiting ribonucleotide reductase. Strong Pseudomonas aeruginosa. They believe that this new method will greatly reduce the difficulty in the development of ribonucleotidylase inhibitors and help develop new anti-cancer drugs.